Asset
SAMIDORPHAN
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01903837 | phase2 | completed | 2013-06-01 | 2014-12-01 | Alkermes, Inc. | A Study of ALKS 3831 in Adults With Schizophrenia |
| NCT02161718 | phase2 | completed | 2014-05-01 | 2017-01-11 | Alkermes, Inc. | A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder |
| NCT02218021 | phase1 | completed | 2014-08-01 | 2014-11-01 | Alkermes, Inc. | A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users |
| NCT00800319 | phase1 | completed | 2008-12-01 | 2009-02-01 | Alkermes, Inc. | ALK33-001: A Study of RDC-0313 Administered to Healthy Adults |
| NCT01098435 | phase2 | completed | 2010-05-01 | 2011-05-01 | Alkermes, Inc. | ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder |
FDA applications (0)
This company has no applications containing this asset.